Cargando…
Dynamic and static circulating cancer microRNA biomarkers – a validation study
For cancers and other pathologies, early diagnosis remains the most promising path to survival. Profiling of longitudinal cohorts facilitates insights into trajectories of biomarkers. We measured microRNA expression in 240 serum samples from patients with colon, lung, and breast cancer and from canc...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754110/ https://www.ncbi.nlm.nih.gov/pubmed/36511578 http://dx.doi.org/10.1080/15476286.2022.2154470 |
_version_ | 1784851115036114944 |
---|---|
author | Abu-Halima, Masood Keller, Andreas Becker, Lea Simone Fischer, Ulrike Engel, Annika Ludwig, Nicole Kern, Fabian Rounge, Trine B. Langseth, Hilde Meese, Eckart Keller, Verena |
author_facet | Abu-Halima, Masood Keller, Andreas Becker, Lea Simone Fischer, Ulrike Engel, Annika Ludwig, Nicole Kern, Fabian Rounge, Trine B. Langseth, Hilde Meese, Eckart Keller, Verena |
author_sort | Abu-Halima, Masood |
collection | PubMed |
description | For cancers and other pathologies, early diagnosis remains the most promising path to survival. Profiling of longitudinal cohorts facilitates insights into trajectories of biomarkers. We measured microRNA expression in 240 serum samples from patients with colon, lung, and breast cancer and from cancer-free controls. Each patient provided at least two serum samples, one prior to diagnosis and one following diagnosis. The median time interval between the samples was 11.6 years. Using computational models, we evaluated the circulating profiles of 21 microRNAs. The analysis yielded two sets of biomarkers, static ones that show an absolute difference between certain cancer types and controls and dynamic ones where the level over time provided higher diagnostic information content. In the first group, miR-99a-5p stands out for all three cancer types. In the second group, miR-155-5p allows to predict lung cancers and colon cancers. Classification in samples from cancer and non-cancer patients using gradient boosted trees reached an average accuracy of 79.9%. The results suggest that individual change over time or an absolute value at one time point may predict a disease with high specificity and sensitivity. |
format | Online Article Text |
id | pubmed-9754110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-97541102022-12-16 Dynamic and static circulating cancer microRNA biomarkers – a validation study Abu-Halima, Masood Keller, Andreas Becker, Lea Simone Fischer, Ulrike Engel, Annika Ludwig, Nicole Kern, Fabian Rounge, Trine B. Langseth, Hilde Meese, Eckart Keller, Verena RNA Biol Research Paper For cancers and other pathologies, early diagnosis remains the most promising path to survival. Profiling of longitudinal cohorts facilitates insights into trajectories of biomarkers. We measured microRNA expression in 240 serum samples from patients with colon, lung, and breast cancer and from cancer-free controls. Each patient provided at least two serum samples, one prior to diagnosis and one following diagnosis. The median time interval between the samples was 11.6 years. Using computational models, we evaluated the circulating profiles of 21 microRNAs. The analysis yielded two sets of biomarkers, static ones that show an absolute difference between certain cancer types and controls and dynamic ones where the level over time provided higher diagnostic information content. In the first group, miR-99a-5p stands out for all three cancer types. In the second group, miR-155-5p allows to predict lung cancers and colon cancers. Classification in samples from cancer and non-cancer patients using gradient boosted trees reached an average accuracy of 79.9%. The results suggest that individual change over time or an absolute value at one time point may predict a disease with high specificity and sensitivity. Taylor & Francis 2022-12-13 /pmc/articles/PMC9754110/ /pubmed/36511578 http://dx.doi.org/10.1080/15476286.2022.2154470 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Abu-Halima, Masood Keller, Andreas Becker, Lea Simone Fischer, Ulrike Engel, Annika Ludwig, Nicole Kern, Fabian Rounge, Trine B. Langseth, Hilde Meese, Eckart Keller, Verena Dynamic and static circulating cancer microRNA biomarkers – a validation study |
title | Dynamic and static circulating cancer microRNA biomarkers – a validation study |
title_full | Dynamic and static circulating cancer microRNA biomarkers – a validation study |
title_fullStr | Dynamic and static circulating cancer microRNA biomarkers – a validation study |
title_full_unstemmed | Dynamic and static circulating cancer microRNA biomarkers – a validation study |
title_short | Dynamic and static circulating cancer microRNA biomarkers – a validation study |
title_sort | dynamic and static circulating cancer microrna biomarkers – a validation study |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754110/ https://www.ncbi.nlm.nih.gov/pubmed/36511578 http://dx.doi.org/10.1080/15476286.2022.2154470 |
work_keys_str_mv | AT abuhalimamasood dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy AT kellerandreas dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy AT beckerleasimone dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy AT fischerulrike dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy AT engelannika dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy AT ludwignicole dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy AT kernfabian dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy AT roungetrineb dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy AT langsethhilde dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy AT meeseeckart dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy AT kellerverena dynamicandstaticcirculatingcancermicrornabiomarkersavalidationstudy |